Successfully treated severe COVID-19 and invasive aspergillosis in early hematopoietic cell transplantation setting
- PMID: 32959932
- PMCID: PMC7537000
- DOI: 10.1111/tid.13470
Successfully treated severe COVID-19 and invasive aspergillosis in early hematopoietic cell transplantation setting
Keywords: COVID-19 management; hematopoietic cell transplantation; immune suppressed patients; invasive aspergillosis co-infection; ruxolitinib; severe COVID-19.
Conflict of interest statement
The authors of this manuscript have no conflicts of interest to disclose as described by the
Figures
References
-
- De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) C. Clin Infect Dis. 2008;46(12):1813‐1821. 10.1086/588660 - DOI - PMC - PubMed
-
- Azoulay E, Mokart D, Pène F, et al. Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium‐A groupe de recherche respiratoire en réanimation onco‐hématologique study. J Clin Oncol. 2013;31(22):2810‐2818. 10.1200/JCO.2012.47.2365 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
